German court finds Praluent infringes Amgen's German Repatha patent

15 July 2019
patent_trademark_big_li

The Düsseldorf Regional Court has found that Praluent (alirocumab) infringes the German part of US biotech firm Amgen’s (Nasdaq: AMGN) European patent (EP 2 215 124), relating to rival product Repatha (evolocumab), directed to antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

The court granted an injunction prohibiting French pharma major Sanofi (Euronext: SAN) and partner Regeneron Pharmaceuticals’ (Nasdaq: REGN) from manufacture, sale and marketing of Praluent in Germany. For the injunction to go into effect, Amgen must enforce it by posting a bond.

Sanofi and Regeneron said: “We are disappointed in this decision, and continue to believe that patients and physicians should have a choice of cholesterol-lowering therapies in order to achieve optimal lipid-lowering for patients.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology